EXTRACELL BIOTECHNOLOGIES
The computed 12-month bankruptcy probability of EXTRACELL BIOTECHNOLOGIES is 3.5% (moderate). The 2024 annual accounts show negative equity (€-6k) and a net result of €-14k. Its solvency ranks better than 5% of 174 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-6k |
| Net result | €-14k |
| Better than sector | 5% |
| Active | 3 yrs |
Mixed profile: strong on profitability, weaker on health.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -2159.1% | 55.0% | |
| Net result | €-14k | €16k | |
| Equity | €-6k | €70k | |
| Gross operating margin | €-14k | €41k | |
| Total assets | €301 | €145k |
| Fiscal year | 2024 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | - |
| Net profit | €-14k |
| Cash flow | - |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €301 |
| Equity | €-6k |
| Debt | €7k |
| of which ≤ 1y | €7k |
| of which > 1y | - |
| Working capital | €-6k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.04 |
| Quick ratio | 0.04 |
| Working capital ratio | -2159.1% |
| Solvency | -2159.1% |
| Debt / equity | -1.05 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -4665.8% |
| ROE | 216.1% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | 6d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €301 |
| Current assets | 29/58 | €301 |
| Amounts receivable within one year | 40/41 | €286 |
| Cash & bank | 54/58 | €15 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €301 |
| Equity | 10/15 | €-6k |
| Contributions / capital | 10/11 | €10k |
| Accumulated profits (losses) | 14 | €-16k |
| Amounts payable | 17/49 | €7k |
| Amounts payable within one year | 42/48 | €7k |
| Trade debts payable within one year | 44 | €226 |
| Income statement | ||
| Gross operating margin | 9900 | €-14k |
| Operating result | 9901 | €-14k |
| Financial charges | 65 | €25 |
| Result before taxes | 9903 | €-14k |
| Net result for the period | 9904 | €-14k |
| Result to be appropriated | 9905 | €-14k |
| NACE primary | 72101 |
| Legal form | Private limited company(610) |
| Incorporation | 03-08-2023 |
| Status | Active |
| Postal code | 4031 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62002C0005/00W002 | Wallonia | 1.6 ha | 1 · 1,586 m² | 15.9 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
12-10-2023 Registered office moved from LIEGE to ANGLEUR
- Avenue de l'Hôpital, 1 4000 LIEGE → Liège Science Park, RISE Bâtiment B60 Rué Pré Aily, 4 4031 ANGLEUR
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Li\u00E8ge Science Park, RISE B\u00E2timent B60\nRu\u00E9 Pr\u00E9 Aily, 4\n4031 ANGLEUR",
"city": "ANGLEUR",
"region": "waals_gewest",
"street": "Ru\u00E9 Pr\u00E9 Aily",
"country": "BE",
"postcode": "4031",
"box_number": null,
"street_number": "4",
"locality_suffix": null
},
"old_address": {
"raw": "Avenue de l\u0027H\u00F4pital, 1 4000 LIEGE",
"city": "LIEGE",
"region": "waals_gewest",
"street": "Avenue de l\u0027H\u00F4pital",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "1",
"locality_suffix": null
},
"effective_date": null,
"evidence_quote": "En date du 18 septembre 2023, conform\u00E9ment \u00E0 l\u0027article 2 des statuts de la soci\u00E9t\u00E9, les administrateurs ont approuv\u00E9 \u00E0 l\u0027unanimit\u00E9 le d\u00E9placement du si\u00E8ge social de l\u0027entreprise \u00E0 l\u0027adresse suivante:",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "header_volledig_adres",
"statute_clause_text": null,
"statute_article_number": 2,
"effective_date_qualifier": "not_specified",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": null,
"filing_date": "2023-09-18",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "algemene_vergadering",
"date": "2023-09-18",
"unanimous": true
},
"subject_company": {
"kbo": "0804.532.945",
"name_full": "EXTRACELL BIOTECHNOLOGIES",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Cl\u00E9ment Nshimiyimana",
"org_rep_person_name": null,
"person_role_at_subject": "Administrateur"
},
"co_filed_documents": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | EXTRACELL BIOTECHNOLOGIES |
| AbbreviationFR | ExtraCell |